Getting interesting. Can not wait for the pop, run, and squeeze.
Those of you who understand technical know what I am talking about. It is why the short trade here is doomed.
So they try to keep shorting to a lower level to allow covering. But the price doesn't go down enough. Just ask the shorts trapped from under 4. This only ends in tears for the shorts.
You must be kidding. The real question dimwit is why anyone should go or should stay long at the current price level. You have to answer the question shorty, not us.
All we need is one of the big shorts to call time and start covering. It could and will happen at any minute, for apparently no reason. Many times it happens in the AM premarket, someone just pulls the trigger and decides to be the first to cover.
They are setting themselves up - they don't need any help from Kovner or any of the longs. Greed will be their undoing.
Keep up the Street, Motley Fool and other misleading "journalism". Just sucking more suckers into the short trade. Retail shorts might as well put a gun to their head and play Russian Roulette. They don't even understand that Phase 3 has now been DERISKED, not made more risky. The shares should be trading well above 7 on the news, and don't worry, the artificially low price will be corrected. Just like when longs get too carried away on the upside, shorts getting too carried away also tend to get their comeuppance. We only have three and a half trading days before earnings. Expect to see some big short covering. And also some news during the week.
You been manwiched!
Hey javedkhan, you want to talk, then you stop posting under the 4.50 post. Otherwise we going to think you keeping that post high up for a reason.
No one drops earnings into the AM early in the week unless they expect some good follow through. Management could have dropped earnings later in the week, but first thing Monday AM. Nice.
Going to trap some shorties over the weekend. Pig short roast yes sar!
Let us know if you will attend by replying or giving the thumbs up.
Courtesy of the management.
Stifel was erring to the most extreme case, of course, because it suits the analyst's agenda. He has been on a Hold with no price target since announcing coverage last year (classic sign of a short biased analyst), and has a slew of hedge funds clients short in the stock. I wouldn't pay any attention to his comments (his comments read like a litany of misleading half truths and outright erroneous comments meant to raise doubt and depress the share price, always conveniently omitting positive points and often outright misleading readers), they are as objective, realistic and honest as AF's.
1) Retraced from 7 to the current level in two days (yes, the shorts starting selling TWO days ago, remember?). That is over 30%. Good entry point technically, RSI oversold (although a print under 20 would be dynamite for entry).
2) At least 2 million more shorts net over last two days. Now over 22m shares short. Almost 55% of the float. And even a higher number when some of the non lent float is taken into account for - so shorts are set up for the kill on the squeeze.
3) "Discussions" from shorts on this board about financing miss the mark - on purpose, because financing would drive shares up in value, not down. The shorts would love to bash saying that a dilutive financing is just around the corner, but in pre commercial biotech, where isn't there a financing around the corner? LOL. It is in the share price already. And I would argue that shorts would love for there to be no financing for just a few more months, because then they could change their tactics from warning about dilution to warning about BK, etc. That is the way these human slugs work.
Fact is that last time the company did a financing with insiders (Kovner and Co. late last year), the shares went up almost 50% in the following three months. We get a financing here, we are not going down on the news, we will trend and move up.
4) AF and his buddy at Stifel both banged their pots yesterday and tried to talk about how things were looking so much more risky here - but it is complete garbage. The decay in HR is normal with all studies, was more than priced into the shares following what happened at ASCO, and is still below the .80 magic threshold needed for approval. And AF and his Stifel partner in crime were comparing apples and oranges to mislead - phase 2 is all about finding the right population in order to make sure that phase 3 is a statistical success. The news this weekend DERISKED phase 3, not made it more risky as these schmucks said. Synta was able to identify the right population, HR .63.